Pfizer COVID-19 Vaccine Sales Tumble
Digest more
The new Moderna COVID vaccine, mNexspike, is approved for adults 65 and older and people 12 to 64 with an underlying medical condition that puts them at higher risk for severe COVID.
Medpage Today on MSN
Salmonella Paratyphi A Vaccine Protected Against Infection
An investigational live attenuated vaccine led to protection against Salmonella enterica serovar Paratyphi A infection, according to a phase IIb randomized trial using a controlle
The 2025 flu season has begun, and the new flu vaccine was released in the United States in September. Influenza viruses are unique in their ability to […]
In Ohio, a law exists that provides religious and medical vaccine exemptions for children in daycares, preschools and K-12 schools.
FOX6 News Milwaukee on MSN
Shingles vaccine could have major secondary benefits new study suggests
The shingles vaccine is intended to prevent a painful rash caused by the reactivation of a virus – but a new study suggests that it could have major secondary benefits.
Vaccine policy nearly tore the nation apart during the pandemic. But solid majorities of Georgians, of all parties and age groups, support a mandate for parents to have their children vaccinated against diseases such as polio and measles.
KELO Sioux Falls on MSN
How vaccine hesitancy can become conviction in SD
Natasha Smith has seen her views on vaccines transform. “I had been reading books about pregnancy and parenthood of toddlers, that sort of a thing, and the author of those books ended up veering into kind of an anti-vaccination realm,
Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting the protein essential to tumor cell growth and by adding a key signal to boost the immune system response.
The results bolster confidence in Takeda’s two-dose regimen, especially as countries grapple with record dengue outbreaks fueled by climate change.
Job cuts are coming to a Redmond-based vaccine company. Inventprise plans to lay off 76 employees, according to a state filing. The first cuts start on December 31, with more in early 2026. Workers in Redmond and Woodinville, where the company manufactures vaccines, will be affected, according to The Puget Sound Business Journal.